

Lieve Brochez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/529045/publications.pdf>

Version: 2024-02-01

95
papers

3,119
citations

126907

33
h-index

168389

53
g-index

100
all docs

100
docs citations

100
times ranked

5457
citing authors

#	ARTICLE	IF	CITATIONS
1	Basal cell carcinoma in older adults: how to decide when active surveillance or watchful waiting is appropriate?. British Journal of Dermatology, 2022, 187, 244-245.	1.5	4
2	The value of measuring uncertainty in neural networks in dermoscopy. Journal of the American Academy of Dermatology, 2022, , .	1.2	0
3	Skin Cancer Detection Using Infrared Thermography: Measurement Setup, Procedure and Equipment. Sensors, 2022, 22, 3327.	3.8	22
4	Health state utility instruments in patients with keratinocyte cancer and actinic keratosis: a cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	3
5	Lesion-directed screening to optimize skin cancer detection in dermatology practice: an observational study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1309-1314.	2.4	5
6	Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer, 2021, 21, 514.	2.6	10
7	Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures. Cancers, 2021, 13, 2630.	3.7	3
8	Three-dimensional margin assessment in head and neck malignancies using a submillimetric 18F-FDG PET/CT, results of an ongoing clinical trial. Oral Oncology, 2021, 118, 5.	1.5	0
9	High-Resolution 18F-FDG PET/CT for Assessing Three-Dimensional Intraoperative Margins Status in Malignancies of the Head and Neck, a Proof-of-Concept. Journal of Clinical Medicine, 2021, 10, 3737.	2.4	13
10	26915 Steps towards trustworthy AI: Detecting unsupported lesions. Journal of the American Academy of Dermatology, 2021, 85, AB26.	1.2	1
11	Clinical Relevance of Serum Kyn/Trp Ratio and Basal and IFN γ -Upregulated IDO1 Expression in Peripheral Monocytes in Early Stage Melanoma. Frontiers in Immunology, 2021, 12, 736498.	4.8	8
12	Dynamic Infrared Thermography (DIRT) in Biomedical Applications: DIEP Flap Breast Reconstruction and Skin Cancer. Engineering Proceedings, 2021, 8, 3.	0.4	1
13	Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 789473.	4.8	2
14	IDO Expression in Cancer: Different Compartment, Different Functionality?. Frontiers in Immunology, 2020, 11, 531491.	4.8	104
15	Recommendations for skin cancer consultation and surgery during COVID-19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1876-1878.	2.4	6
16	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. Cancer Research, 2020, 80, 2983-2995.	0.9	51
17	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunology, Immunotherapy, 2020, 69, 2589-2598.	4.2	44
18	Enhanced visualization of blood and pigment in multispectral skin dermoscopy. Skin Research and Technology, 2020, 26, 708-712.	1.6	10

#	ARTICLE	IF	CITATIONS
19	Charting Extracellular Transcriptomes in The Human Biofluid RNA Atlas. <i>Cell Reports</i> , 2020, 33, 108552.	6.4	50
20	Abstract PR15: Charting extracellular transcriptomes in The Human Biofluid RNA Atlas. , 2020, , .		0
21	Haptoglobin polymorphism and the risk of actinic keratoses and cutaneous squamous cell carcinoma: A caseâ€“control study. <i>Journal of Dermatology</i> , 2019, 46, 274-275.	1.2	2
22	Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2019, 75, 707-711.	1.9	89
23	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 828-835.	0.8	46
24	Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?. <i>Current Opinion in Oncology</i> , 2019, 31, 54-64.	2.4	66
25	Value of Dermoscopy in a Population-Based Screening Sample by Dermatologists. <i>Dermatology Practical and Conceptual</i> , 2019, 9, 200-206.	0.9	7
26	Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 422-422.	1.6	0
27	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. <i>Neoplasia</i> , 2018, 20, 218-225.	5.3	31
28	Phase 1 Dose Escalation Trial of Ipilimumab andÂStereotactic Body Radiation Therapy in Metastatic Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 906-915.	0.8	30
29	A CARD9 Founder Mutation Disrupts NF-Î²B Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation. <i>Frontiers in Immunology</i> , 2018, 9, 2366.	4.8	46
30	Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review. <i>Case Reports in Dermatology</i> , 2018, 10, 190-197.	0.8	54
31	OC-0682: Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 127, S357-S358.	0.6	1
32	Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. <i>Nature Communications</i> , 2018, 9, 2921.	12.8	26
33	Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. <i>Oncotarget</i> , 2018, 9, 25216-25224.	1.8	26
34	A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response. <i>Journal of Translational Medicine</i> , 2017, 15, 21.	4.4	21
35	The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. <i>European Journal of Cancer</i> , 2017, 76, 167-182.	2.8	234
36	Cost-effectiveness and Budget Effect Analysis of a Population-Based Skin Cancer Screening. <i>JAMA Dermatology</i> , 2017, 153, 147.	4.1	21

#	ARTICLE	IF	CITATIONS
37	Pathologic Evaluation of Skin Tumors With Ex Vivo Dermoscopy With Derm Dotting. JAMA Dermatology, 2017, 153, 154.	4.1	9
38	OC-0017: Combined High Dose Radiation and Ipilimumab in Metastatic Melanoma, a Phase I Dose Escalation Trial. Radiotherapy and Oncology, 2017, 123, S5.	0.6	0
39	Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. European Journal of Cancer, 2017, 86, 358-363.	2.8	72
40	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Journal of Translational Medicine, 2017, 15, 150.	4.4	26
41	Successful strategy to treat a solitary cystic melanoma brain metastasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e216-e217.	2.4	0
42	Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL).. Journal of Clinical Oncology, 2017, 35, e21006-e21006.	1.6	1
43	Long non-coding RNAs in cutaneous melanoma: clinical perspectives. Oncotarget, 2017, 8, 43470-43480.	1.8	35
44	Systemic treatment influences on immune accessibility of melanoma: A retrospective histopathological investigation. Annals of Oncology, 2016, 27, vi388.	1.2	0
45	Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening. British Journal of Dermatology, 2016, 174, 1258-1265.	1.5	56
46	Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents. Journal of Clinical Gastroenterology, 2016, 50, 438.	2.2	3
47	Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure. Preventive Medicine, 2016, 93, 177-182.	3.4	34
48	Chemoprevention of basal cell carcinoma: reply from authors. British Journal of Dermatology, 2016, , .	1.5	0
49	Chemoprevention of basal cell carcinoma: reply from authors. British Journal of Dermatology, 2016, 175, 1404-1405.	1.5	0
50	Chronic and Invasive Fungal Infections in a Family with CARD9 Deficiency. Journal of Clinical Immunology, 2016, 36, 204-209.	3.8	98
51	Comparison of Ex Vivo and In Vivo Dermoscopy in Dermatopathologic Evaluation of Skin Tumors. JAMA Dermatology, 2016, 152, 312.	4.1	10
52	Total-Body Examination vs Lesion-Directed Skin Cancer Screening. JAMA Dermatology, 2016, 152, 27.	4.1	51
53	Rosettes and other white shiny structures in polarized dermoscopy: histological correlate and optical explanation. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 311-313.	2.4	47
54	Systemic immune changes associated with adjuvant interferon- β therapy in stage III melanoma patients. Melanoma Research, 2015, 25, 357-361.	1.2	13

#	ARTICLE	IF	CITATIONS
55	Phase I trial of stereotactic body radiotherapy with concurrent fixed dose ipilimumab in metastatic melanoma: Dose limiting toxicity and abscopal effect. <i>Annals of Oncology</i> , 2015, 26, viii5.	1.2	0
56	Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 9.	4.4	54
57	A short dermoscopy training increases diagnostic performance in both inexperienced and experienced dermatologists. <i>Australasian Journal of Dermatology</i> , 2015, 56, 52-55.	0.7	17
58	Characterization of the <i>in vivo</i> immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. <i>Oncolmunology</i> , 2015, 4, e982382.	4.6	95
59	Efficacy of Products to Remove Eggs of <i>Pediculus humanus capitis</i> (Phthiraptera: Pediculidae) From the Human Hair. <i>Journal of Medical Entomology</i> , 2014, 51, 400-407.	1.8	12
60	Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. <i>Endocrine</i> , 2014, 47, 878-883.	2.3	37
61	Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?. <i>British Journal of Dermatology</i> , 2014, 171, 987-995.	1.5	63
62	Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 741-746.	2.4	39
63	Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. <i>Cell Death and Differentiation</i> , 2014, 21, 1250-1261.	11.2	195
64	A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 507-511.	2.4	30
65	Cancer risk in immune-mediated inflammatory diseases (IMID). <i>Molecular Cancer</i> , 2013, 12, 98.	19.2	104
66	The distribution pattern of segmental vitiligo: clues for somatic mosaicism. <i>British Journal of Dermatology</i> , 2013, 168, 56-64.	1.5	33
67	miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. <i>International Journal of Oncology</i> , 2013, 42, 1443-1451.	3.3	76
68	Clinical significance of Koebner phenomenon in vitiligo. <i>British Journal of Dermatology</i> , 2012, 167, 1017-1024.	1.5	25
69	In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 57-65.	3.3	36
70	Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. <i>European Journal of Cancer</i> , 2012, 48, 2004-2011.	2.8	92
71	Immune mediated mechanisms of melanocyte destruction. <i>Oncolmunology</i> , 2012, 1, 526-528.	4.6	4
72	The haptoglobin phenotype influences the risk of cutaneous squamous cell carcinoma in kidney transplant patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 566-571.	2.4	12

#	ARTICLE	IF	CITATIONS
73	Halo naevi with associated vitiligo-like depigmentations: pathogenetic hypothesis. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 755-761.	2.4	18
74	New insights in segmental vitiligo: case report and review of theories. British Journal of Dermatology, 2012, 166, 240-246.	1.5	61
75	Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations. Expert Opinion on Drug Delivery, 2011, 8, 705-720.	5.0	68
76	Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell and Melanoma Research, 2011, 24, 334-344.	3.3	45
77	P032. Indoleamine 2,3 dioxygenase. Melanoma Research, 2011, 21, e34.	1.2	0
78	P069. The haptoglobin phenotype influences the risk of cutaneous squamous cell carcinoma in kidney transplant patients. Melanoma Research, 2011, 21, e55.	1.2	0
79	Prognostic value and clinical significance of halo naevi regarding vitiligo. British Journal of Dermatology, 2011, 164, 743-749.	1.5	31
80	Different phenotypes of segmental vitiligo based on a clinical observational study. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 673-678.	2.4	31
81	EGFR in melanoma: clinical significance and potential therapeutic target. Journal of Cutaneous Pathology, 2011, 38, 492-502.	1.3	77
82	Association of haptoglobin phenotypes with the development of Kaposi's sarcoma in HIV patients. Archives of Dermatological Research, 2011, 303, 763-769.	1.9	10
83	Dermatological side effects of current and upcoming targeted therapies in oncology. Acta Clinica Belgica, 2011, 66, 97-103.	1.2	6
84	Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. European Journal of Dermatology, 2010, 20, 425-433.	0.6	93
85	P-cadherin counteracts myosin II-B function: implications in melanoma progression. Molecular Cancer, 2010, 9, 255.	19.2	19
86	Superficial granulomatous pyoderma with ocular involvement. European Journal of Dermatology, 2010, 20, 648-9.	0.6	0
87	The role of RhoC in growth and metastatic capacity of melanoma. Journal of Cutaneous Pathology, 2009, 36, 629-636.	1.3	31
88	Clinical significance of the expression of c-Ski and SnoN, possible mediators in TGF- β resistance, in primary cutaneous melanoma. Journal of Dermatological Science, 2009, 53, 26-33.	1.9	23
89	The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2008, 453, 257-265.	2.8	46
90	Incidence of scabies in Belgium. Epidemiology and Infection, 2008, 136, 395-398.	2.1	18

#	ARTICLE	IF	CITATIONS
91	Dysplastic Nevi. New England Journal of Medicine, 2003, 349, 2233-2240.	27.0	90
92	The melanoma burden in Belgium; premature morbidity and mortality make melanoma a considerable health problem. Melanoma Research, 1999, 9, 614-618.	1.2	17
93	Hypomelanoses Associated with Melanocytic Neoplasia. , 0, , 705-724.		2
94	Charting Extracellular Transcriptomes in the Human Biofluid RNA Atlas. SSRN Electronic Journal, 0, , .	0.4	4
95	Randomized Phase 1 Trial of Pembrolizumab with Neo-Adjuvant Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. SSRN Electronic Journal, 0, , .	0.4	0